SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
NVAX reported Q3 2026 results. The stock moved -8.2% on the print.
NVAXearnings

Earnings reactions, page 6

Novavax, Inc. (NVAX) Q3 FY2026 earnings

November 5, 2026 · SharpeIQ Research Desk

Reported results

  • Total revenue was $68 million (or $68,298 thousand) for the third quarter of 2026, compared to $70 million (or $70,445 thousand) for the same period in 2025 under GAAP.
  • Product sales were $26 million (or $25,693 thousand) for the third quarter of 2026 under GAAP.
  • Licensing, royalties and other revenue were $43 million (or $42,605 thousand) for the third quarter of 2026 under GAAP.
  • Research and development expenses were $52 million (or $52,446 thousand) for the third quarter of 2026 under GAAP.
  • Selling, general and administrative expenses were $24 million (or $23,645 thousand) for the third quarter of 2026 under GAAP.
  • Net loss was $31 million (or $31,376 thousand) for the third quarter of 2026 under GAAP.

Guidance

  • Combined R&D and SG&A Expenses Full Year 2026 guidance is $375 - $395 million.
  • Non-GAAP Combined R&D and SG&A Expenses Full Year 2026 guidance is $315 - $335 million.
  • Nuvaxovid Product Sales Full Year 2026 guidance is $40 - $50 million.
  • Adjusted Supply Sales Full Year 2026 guidance is $50 - $60 million.
  • Sanofi CIC Milestone Full Year 2026 guidance is $125 million.
  • Adjusted Licensing, Royalties and Other Revenue Full Year 2026 guidance is $170 - $180 million.
  • Adjusted Total Revenue Full Year 2026 guidance is $385 - $415 million.

Price and volatility reaction

The stock moved -8.2% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -1.1 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release10.652026-11-04
Close after release9.782026-11-05
Realised move-8.2%close to close
30d ATM IV change-1.1 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-11-05 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →